Argos Therapeutics Inc (NASDAQ:ARGS) CFO Richard D. Katz sold 101,228 shares of Argos Therapeutics stock in a transaction dated Wednesday, January 3rd. The shares were sold at an average price of $0.16, for a total value of $16,196.48. Following the completion of the sale, the chief financial officer now owns 298,394 shares of the company’s stock, valued at $47,743.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Argos Therapeutics Inc (ARGS) traded down $0.02 during mid-day trading on Friday, hitting $0.17. The company had a trading volume of 6,577,500 shares, compared to its average volume of 6,273,333. The company has a debt-to-equity ratio of -1.46, a current ratio of 2.29 and a quick ratio of 2.29. The company has a market capitalization of $14.07, a P/E ratio of -0.15 and a beta of 1.38. Argos Therapeutics Inc has a 12-month low of $0.13 and a 12-month high of $5.68.
A hedge fund recently bought a new stake in Argos Therapeutics stock. Wasatch Advisors Inc. acquired a new stake in Argos Therapeutics Inc (NASDAQ:ARGS) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 665,831 shares of the biopharmaceutical company’s stock, valued at approximately $120,000. Wasatch Advisors Inc. owned approximately 1.21% of Argos Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 18.35% of the company’s stock.
About Argos Therapeutics
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
Receive News & Ratings for Argos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.